The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPolar Capital Regulatory News (POLR)

Share Price Information for Polar Capital (POLR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 538.00
Bid: 538.00
Ask: 542.00
Change: -3.00 (-0.55%)
Spread: 4.00 (0.743%)
Open: 538.00
High: 538.00
Low: 538.00
Prev. Close: 541.00
POLR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Team Acquisition Completion

19 Oct 2020 07:00

RNS Number : 3843C
Polar Capital Holdings PLC
19 October 2020
 

19 October 2020

 

Polar Capital Holdings plc completes the acquisition of International and World equity strategies

 

Polar Capital Holdings plc ("Polar Capital"), the specialist active asset management group, today announces the completion of the acquisition of the International Value and World Value equity team led by Pierre Py and Greg Herr ("the Managers") from the Los Angeles-based asset manager First Pacific Advisors, LP.

- A new joint venture, Phaeacian Partners LLC ("Phaeacian"), has been established

- Two 1940 Act mutual funds - the FPA Paramount Fund, Inc. and the FPA International Value Fund - have been reorganised into the Phaeacian Global Value Fund and the Phaeacian Accent International Value Fund

- Phaeacian assets under management at the transition total $545m (as at the end of September 2020)

The completion of the transaction provides the Managers and Polar Capital with the opportunity to build Phaeacian into a significant presence in the International (global ex-US) and Global equity sectors.

The Managers bring an exceptional performance record. Over five years to end September 2020, the FPA International Value Fund is five-star rated by Morningstar and the FPA Paramount Fund is four-star rated. Additionally, International Value is the top ranked fund in its Morningstar sector over three and five years and holds a Morningstar Bronze rating*. All performance track records and ratings have been ported across to Phaeacian.

The launch and establishment of Phaeacian is consistent with Polar Capital's strategy of diversifying its product offering into top-performing international and global equity strategies, as with its Emerging Markets Stars business, with appeal in the institutional as well as wholesale channels, particularly in North America.

 

Gavin Rochussen, CEO, Polar Capital said:

"The establishment of Phaeacian Partners is the next step in Polar's strategy to build out our international and global products and our institutional presence in North America.

 

"The strategies that Pierre and Greg will manage for us, as well as their investment philosophy, are a natural fit with Polar Capital's investment-led approach to managing our clients' money. We will provide Phaeacian with a best-in-class operational structure, allowing them the investment autonomy to build on their impressive track record and proven, repeatable investment process. They are an excellent addition to Polar Capital, and I am looking forward to working with them."

 

Pierre Py and Greg Herr said:

"We are thoroughly looking forward to working with Polar Capital. The partnership allows us to focus on generating exceptional, investment-led returns for our clients, while benefiting from the outstanding business support Polar Capital can provide. It is an ideal fit for us in terms of operating environment and culture."

 

*Source: Morningstar as at 30 September 2020. FPA International Value is in the Morningstar Foreign Small/Mid Blend Morningstar category and FPA Paramount in the Morningstar World Large Stock category.

For further information please contact:

Polar Capital + 44 (0)20 7227 2700

Gavin Rochussen (Chief Executive)

John Mansell (Executive Director)

Samir Ayub (Finance Director)

 

Numis Securities Limited - Nomad and Joint Broker + 44 (0) 20 7260 1000

Charles Farquhar

Stephen Westgate

Kevin Cruickshank (QE)

 

Peel Hunt LLP - Joint Broker +44 (0)20 7418 8893

Andrew Buchanan

Rishi Shah

 

Camarco +44 (0)20 3757 4984

Ed Gascoigne-Pees

Georgia Edmonds

Monique Perks

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STRBUBDGGXBDGGL
Date   Source Headline
9th Jul 20207:00 amRNSAuM Update
7th Jul 20208:03 amRNSHolding(s) in Company
6th Jul 202010:08 amRNSDirector/PDMR Shareholding
3rd Jul 20207:00 amRNSForm 8.3 - Cello Health PLC
2nd Jul 20209:19 amRNSDirector/PDMR Shareholding
1st Jul 20202:10 pmRNSIssue of Equity
1st Jul 20207:00 amRNSTotal Voting Rights
29th Jun 202010:03 amRNSDirector/PDMR Shareholding
26th Jun 20201:10 pmRNSAnnual Financial Report
25th Jun 202010:26 amRNSHolding(s) in Company
25th Jun 202010:25 amRNSDirector/PDMR Shareholding
24th Jun 20203:29 pmRNSIssue of Equity
22nd Jun 20204:04 pmRNSDividend Declaration
22nd Jun 20207:00 amRNSGroup Audited Results for year ended 31 March 2020
18th Jun 202012:08 pmRNSSecond Price Monitoring Extn
18th Jun 202012:02 pmRNSPrice Monitoring Extension
5th Jun 202010:31 amRNSDirector/PDMR Shareholding
4th Jun 20207:16 amRNSNotice of Results
1st Jun 20207:00 amRNSTotal Voting Rights
19th May 20202:00 pmRNSIssue of Equity
12th May 202010:22 amRNSDirector/PDMR Shareholding
11th May 20201:15 pmRNSDirectorate Change
6th May 202011:36 amRNSHolding(s) in Company
4th May 20201:07 pmRNSIssue of Equity
4th May 202011:24 amRNSDirector/PDMR Shareholding
15th Apr 202012:00 pmRNSFund Termination
9th Apr 20204:26 pmRNSDirectorate Change
9th Apr 202012:02 pmRNSHolding(s) in Company
9th Apr 20207:00 amRNSAuM Update
7th Apr 20204:40 pmRNSSecond Price Monitoring Extn
7th Apr 20204:35 pmRNSPrice Monitoring Extension
7th Apr 20207:00 amRNSBoard Changes
1st Apr 20207:00 amRNSTotal Voting Rights
30th Mar 202012:08 pmRNSSecond Price Monitoring Extn
30th Mar 202012:02 pmRNSPrice Monitoring Extension
19th Mar 20204:41 pmRNSSecond Price Monitoring Extn
19th Mar 20204:37 pmRNSPrice Monitoring Extension
19th Mar 202012:07 pmRNSSecond Price Monitoring Extn
19th Mar 202012:03 pmRNSPrice Monitoring Extension
12th Mar 20208:37 amRNSIssue of Equity
2nd Mar 20207:00 amRNSTotal Voting Rights
28th Feb 20204:41 pmRNSSecond Price Monitoring Extn
28th Feb 20204:36 pmRNSPrice Monitoring Extension
21st Feb 202011:51 amRNSForm 8.3 - Redde PLC
21st Feb 20209:59 amRNSIssue of Equity
20th Feb 20201:54 pmRNSForm 8.3 - Redde PLC
18th Feb 202011:14 amRNSForm 8.3 - Redde PLC
18th Feb 202010:28 amRNSChange of Auditor
17th Feb 20202:44 pmRNSForm 8.3 - Redde PLC
13th Feb 20202:37 pmRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.